Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

PP-14, a Novel Structurally-Enhanced Antisickling Allosteric Hemoglobin Effector, Increases Oxygen Affinity and Disrupts Hemoglobin S Polymer Formation

Martin K. Safo, PhD, Piyusha P Pagare, PhD, Mohini Ghatge, PhD, Carla Casu, PhD, Valentina Ghiaccio, PhD, Nancy Anabaraonye, Xiaomeng Xu, MS, Stefano Rivella, PhD, Patrick C. Hines, MD PhD, Ke Liu, PhD, Yan Zhang, PhD, Jürgen Venitz, MD PhD, Osheiza Abdulmalik, DVM

Blood (2019) 134 (Supplement_1): 73.

https://doi.org/10.1182/blood-2019-128646

Published: 2019

Journal Articles

SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial

Blood (2019) 134 (Supplement_1): 2651.

https://doi.org/10.1182/blood-2019-127835

Published: 2019

Journal Articles

Copy Number Variations in Cytochromes and Glutathione-Transferases As Early Predictors of the Efficacy of Tyrosine Kinase Inhibitors in CML

Alexander V Lavrov, MD PhD, Oksana A Ustaeva, Elmira P Adilgereeva, Svetlana A Smirnikhina, Ekaterina Chelysheva, MD, Oleg Shukhov, MD, Yuriy V Shatokhin, Sergey V Mordanov, Anna G Turkina, Prof., MD, Sergey Kutsev

Blood (2016) 128 (22): 5457.

https://doi.org/10.1182/blood.V128.22.5457.5457

Published: 2016

Journal Articles

Pharmacokinetics of Bendamustine Hydrochloride in Chinese Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Refractory to Rituximab Treatment

Xiaohong Han, Ning Li, Yuan-Yuan Song, Edward Hellriegel, Philmore Robertson, Yuan-Kai Shi

Blood (2016) 128 (22): 5147.

https://doi.org/10.1182/blood.V128.22.5147.5147

Published: 2016

Journal Articles

Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial

Blood (2016) 128 (22): 4403.

https://doi.org/10.1182/blood.V128.22.4403.4403

Published: 2016

Journal Articles

A Pharmacogenetic Study of the NCIC CTG Clinical Trial My.10: Single Nucleotide Polymorphisms, Prognosis, and Predicting Benefit from IMiD® Compound Maintenance Therapy Following Autologous Stem Cell Transplant for Multiple Myeloma

Ming Han, BSc., Alli Murugesan, MSc, PhD, Nizar J Bahlis, MD, Kevin Song, Darrell White, MD MSc, FRCPC, FACP, Christine Chen, MD, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Kang Howsen-Jan, MD, Donna Reece, Keith Stewart, MD, Yagang Xie, MD PhD FCCMG, Annette E Hay, MB ChB, Lois Shepherd, MD, Bingshu E Chen, PhD, Marina Djurfeldt, MSc., Tony Reiman, MD

Blood (2015) 126 (23): 2960.

https://doi.org/10.1182/blood.V126.23.2960.2960

Published: 2015

Journal Articles

Effect of Renal and Hepatic Function on Pomalidomide Dose in Patients with Relapsed/Refractory Multiple Myeloma

Adriana C Rossi, MD, Ekta Aneja, MBBS, Angelique Boyer, David Jayabalan, BSMS, MSc, Tomer M Mark, MD MSc, Roger Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2014) 124 (21): 4754.

https://doi.org/10.1182/blood.V124.21.4754.4754

Published: 2014

Journal Articles

Evaluation Of CYP450 and Transporter-Mediated Drug-Drug Interaction Potential Of Pomalidomide In Healthy Men and In Vitro

Claudia Kasserra, PhD, Mahmoud Assaf, MS, MBA, Matthew Hoffmann, PhD, Yan Li, PhD, Liangang Liu, PhD, Xiaomin Wang, PhD, Gondi Kumar, PhD, Maria Palmisano, MD

Blood (2013) 122 (21): 1989.

https://doi.org/10.1182/blood.V122.21.1989.1989

Published: 2013

Journal Articles

Correlation Between Red Blood Cell Survival and Cytochrome P450 1A2 Enzyme Activity

Larry J. Dumont, PhD, MBA, Swaroopa Yerrabothala, MD, Gregory J Tsongalis, PhD, Xiaoyun Fu, Ph.D., James C. Zimring, MD, PhD, John Roback, MD, PhD

Blood (2013) 122 (21): 3658.

https://doi.org/10.1182/blood.V122.21.3658.3658

Published: 2013

Journal Articles

Metabolism and Disposition of Betrixaban and Its Lack of Interaction with Major CYP Enzymes.

Athiwat Hutchaleelaha, Ph.D., Christine Ye, Ph.D., Yonghong Song, Ph.D., Todd Lorenz, MD, Daniel Gretler, MD, Joseph L Lambing, Ph.D.

Blood (2012) 120 (21): 2266.

https://doi.org/10.1182/blood.V120.21.2266.2266

Published: 2012

Journal Articles

Pharmacokinetic Exploration of Potential for Bendamustine to Affect Rituximab Concentrations and of Cytochrome P450 1A2 Inhibitors to Affect Bendamustine Concentrations in Patients with Non-Hodgkin and Mantle Cell Lymphoma

Mona Darwish, PhD, Mary Bond, MS, MBA, John M. Burke, MD, Edward T. Hellriegel, PhD, Philmore Robertson, Jr., PhD, Luann Phillips, MS, Thaddeus Grasela, PharmD, PhD

Blood (2012) 120 (21): 4919.

https://doi.org/10.1182/blood.V120.21.4919.4919

Published: 2012

Journal Articles

Low Activity of Cytochrome P450 1A2 (CYP1A2) Enzyme May Protect From Iron Accumulation in Children and Adults with Transfusion Depended β-Thalassemia Major

Shoshana Revel-Vilk, MD, MSc, Itamar Nitzan, MD, Ada Goldfarb, MD, Nilla Hemed, Eyal Shteyer, MD

Blood (2011) 118 (21): 2153.

https://doi.org/10.1182/blood.V118.21.2153.2153

Published: 2011

Journal Articles

Influence of Genetic Polymorphisms in CYP1A2 , CYP2C19, CYP3A4 , GSTP1 , MDR1 and PSMB5 Genes in Toxicity and Response to Induction Therapy in Multiple Myeloma Patients Included in the Trial of the Spanish PETHEMA/GEM 05 for Newly Diagnosed MM Elderly Patients (Age 65 or More)

Blood (2011) 118 (21): 1412.

https://doi.org/10.1182/blood.V118.21.1412.1412

Published: 2011

Journal Articles

Trough Plasma Imatinib Levels and ABCG2 Polymorphisms Are Correlated with Optimal Cytogenetic Responses at 6 Months After Treatment with Standard Dose of Imatinib In Newly Diagnosed CML

Blood (2010) 116 (21): 2272.

https://doi.org/10.1182/blood.V116.21.2272.2272

Published: 2010

Journal Articles

Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma.

Sophie L Corthals, David C Johnson, Yvonne de Knegt, Hartmut Goldschmidt, Henk Lokhorst, Stéphane Minvielle, Florence Magrangeas, Jean-Luc Harousseau, Brian G M Durie, Brian G Van Ness, Gareth J Morgan, Pieter Sonneveld, Hervé Avet Loiseau

Blood (2009) 114 (22): 1794.

https://doi.org/10.1182/blood.V114.22.1794.1794

Published: 2009

Journal Articles

Candidate Pathway Approach of Single Nucleotide Polymorphism On Imatinib Transport/Metabolism Pathway and DNA Repair Enzyme Pathway Associated with Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia.

Jung A. Kim, Dong Hwan Dennis Kim, Young Woong Won, Silvia Park, Hee-Jin Kim, Sun-Hee Kim, Jun Ho Jang, Kihyun Kim, Yeo-Kyeoung Kim, Je-Jung Lee, Hyeoung-Joon Kim, Joon Ho Moon, Sang Kyun Sohn, Chul Won Jung

Blood (2009) 114 (22): 3284.

https://doi.org/10.1182/blood.V114.22.3284.3284

Published: 2009

Journal Articles

Targeted Anti-Tumor Research of Mesenchymal Stem Cells Delivered Enzyme-Prodrug Gene CYP450 .

Jishi Wang, Yuan Yang, Wei Zhang, Pengxiang Guo

Blood (2009) 114 (22): 3582.

https://doi.org/10.1182/blood.V114.22.3582.3582

Published: 2009

Journal Articles

Pharmacokinetic and Pharmacodynamic Properties of SB1317, a Potent and Orally Active Multi-Kinase Inhibitor.

Pauline Yeo, P. Venkatesh, Evelyn Goh, Peizi Zeng, Lee S. New, Changyong Hu, Kanda Sangthongpitag, Anthony D. William, Kee C. Goh, Jeanette M. Wood, Ethirajulu Kantharaj

Blood (2007) 110 (11): 4201.

https://doi.org/10.1182/blood.V110.11.4201.4201

Published: 2007

Journal Articles

Genetic Polymorphisms Correlated with Outcome in Multiple Myeloma Patients Receiving High Dose Melphalan.

Charles Dumontet, MD, PhD, Stefano Landi, PhD, Tony Reiman, MD, PhD, Adriana Plesa, MD, Ilaria Bellini, PhD, Roberto Barale, PhD, Linda M. Pilarski, MD, Sean Tavtigian, PhD, Troy Perry, BsC, Federica Gemignani, PhD

Blood (2007) 110 (11): 4746.

https://doi.org/10.1182/blood.V110.11.4746.4746

Published: 2007

Journal Articles

Preclinical Pharmacokinetic and Metabolism of Apixaban, a Potent and Selective Factor Xa Inhibitor.

Kan He, PhD, Bing He, M.S., James E. Grace, M.S., Baomin Xin, Ph.D., Donglu Zhang, Ph.D., Donald J. Pinto, Ph.D., Joseph M. Luettgen, M.S., Robert M. Knabb, Ph.D., Patrick Y.S. Lam, Ph.D., Ruth R. Wexler, Ph.D., William G. Humphreys, Ph.D., Wen-Chyi Shyu, Ph.D., Scott J. Grossman, Ph.D.

Blood (2006) 108 (11): 910.

https://doi.org/10.1182/blood.V108.11.910.910

Published: 2006

NARROW

PP-14, a Novel Structurally-Enhanced Antisickling Allosteric Hemoglobin Effector, Increases Oxygen Affinity and Disrupts Hemoglobin S Polymer Formation

SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial

Copy Number Variations in Cytochromes and Glutathione-Transferases As Early Predictors of the Efficacy of Tyrosine Kinase Inhibitors in CML

Pharmacokinetics of Bendamustine Hydrochloride in Chinese Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Refractory to Rituximab Treatment

Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial

A Pharmacogenetic Study of the NCIC CTG Clinical Trial My.10: Single Nucleotide Polymorphisms, Prognosis, and Predicting Benefit from IMiD® Compound Maintenance Therapy Following Autologous Stem Cell Transplant for Multiple Myeloma

Effect of Renal and Hepatic Function on Pomalidomide Dose in Patients with Relapsed/Refractory Multiple Myeloma

Evaluation Of CYP450 and Transporter-Mediated Drug-Drug Interaction Potential Of Pomalidomide In Healthy Men and In Vitro

Correlation Between Red Blood Cell Survival and Cytochrome P450 1A2 Enzyme Activity

Metabolism and Disposition of Betrixaban and Its Lack of Interaction with Major CYP Enzymes.

Pharmacokinetic Exploration of Potential for Bendamustine to Affect Rituximab Concentrations and of Cytochrome P450 1A2 Inhibitors to Affect Bendamustine Concentrations in Patients with Non-Hodgkin and Mantle Cell Lymphoma

Low Activity of Cytochrome P450 1A2 (CYP1A2) Enzyme May Protect From Iron Accumulation in Children and Adults with Transfusion Depended β-Thalassemia Major

Influence of Genetic Polymorphisms in CYP1A2 , CYP2C19, CYP3A4 , GSTP1 , MDR1 and PSMB5 Genes in Toxicity and Response to Induction Therapy in Multiple Myeloma Patients Included in the Trial of the Spanish PETHEMA/GEM 05 for Newly Diagnosed MM Elderly Patients (Age 65 or More)

Trough Plasma Imatinib Levels and ABCG2 Polymorphisms Are Correlated with Optimal Cytogenetic Responses at 6 Months After Treatment with Standard Dose of Imatinib In Newly Diagnosed CML

Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma.

Candidate Pathway Approach of Single Nucleotide Polymorphism On Imatinib Transport/Metabolism Pathway and DNA Repair Enzyme Pathway Associated with Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia.

Targeted Anti-Tumor Research of Mesenchymal Stem Cells Delivered Enzyme-Prodrug Gene CYP450 .

Pharmacokinetic and Pharmacodynamic Properties of SB1317, a Potent and Orally Active Multi-Kinase Inhibitor.

Genetic Polymorphisms Correlated with Outcome in Multiple Myeloma Patients Receiving High Dose Melphalan.

Preclinical Pharmacokinetic and Metabolism of Apixaban, a Potent and Selective Factor Xa Inhibitor.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only